CRON Stock Analysis: Buy, Sell, or Hold?
CRON - Cronos Group Inc. Common Share
$2.71
0.02 (0.74%)
▲
5d:
+4.23%
30d:
-1.09%
90d:
+5.04%
BUY
MODERATE Confidence
Analysis Updated: Jun 24, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Smart Money Accumulation
None View Scanner →
Strength: 5.8/10
Get Alerted When CRON Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: CRON shows positive signals but monitor for confirmation. Market pricing in 4.8% decline. Moderate conviction.
💡 BUY OPPORTUNITY: CRON shows positive signals but monitor for confirmation. Market pricing in 4.8% decline. Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: CRON is currently trading at $2.71, which is considered fair relative to its 30-day fair value range of $2.65 to $2.78. From a valuation perspective, the stock is trading at a discount (Forward PE: 18.6) compared to its historical average (21.5). Remarkably, the market is currently pricing in an annual earnings decline of 4.8% over the next few years. This pessimistic expectation contrasts with the company's recent 126.8% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, CRON is in a strong uptrend. Immediate support is located at $2.57, while resistance sits at $2.84.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. However, the stock is trading significantly above the average Wall Street target of $2.40. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CRON is in a strong uptrend. Immediate support is located at $2.57, while resistance sits at $2.84.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. However, the stock is trading significantly above the average Wall Street target of $2.40. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$2.65 -
$2.78
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
70.0%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Trading 11.3% above Wall St target ($2.40)
Trading Range Analysis
30-Day Trading Range
$2.65 -
$2.78
Current vs Trading Range
FAIR
Expected Move (7 Days)
±$0.20
(7.4%)
Support & Resistance Levels
Support Level
$2.57
Resistance Level
$2.84
Current Trend
Strong Uptrend
Technical data as of
Jun 24, 2026
Fundamental Context
Forward P/E (Next Year Est.)
18.56
Wall Street Target
$2.40
(-11.3%)
Revenue Growth (YoY)
40.1%
Earnings Growth (YoY)
126.8%
Profit Margin
-1.1%
Valuation Discount vs History
-4.8% cheaper
PE vs Historical
18.6 vs 21.5
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-4.8%
(market-implied from PE analysis)
1-Year Target
$2.58
(-5%)
2-Year Target
$2.46
(-9%)
3-Year Target
$2.34
(-14%)
3-Yr Target (if PE normalizes)
(PE: 19→22)
$2.71
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 21.9%)
$5.76
(+112%)
Base:
(SPY PE: 18.6, Growth: 21.9%)
$4.91
(+81%)
Bear:
(PE: 15.8, Growth: 21.9%)
$4.17
(+54%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 18.6 to 21.5
Stabilization Target:
$3.14
(+15.8%)
PE Expansion Potential:
+15.8%
Share & Embed Analysis
Last updated: June 24, 2026 5:07 PM ET
Data refreshes hourly during market hours. Next update: 6:07 PM
Data refreshes hourly during market hours. Next update: 6:07 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CRON showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$194 | 59 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$105 | 60 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$125 | 57 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$665 | 60 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 59 HOLD |
Advanced CRON Option Strategies
Professional options setups generated by AI based on today's CRON price and gamma walls.
